Amortization expense for each of the three-month periods ended May 31, 2019 and 2018 was $150,000, and $450,000 for each of the nine-month periods ended May 31, 2019 and 2018.
Amortization expense for each of the three-month periods ended May 31, 2019 and 2018 was $1,875 and was $5,625 for each of the nine-month periods ended May 31, 2019, and 2018.
Amortization expense for the three months and nine months period ended May 31, 2019 was $1,250 and $3,750, respectively.
Amortization expense for each of the three-month and nine-month periods ended May 31, 2019 and 2018 was $89,375 and $268,125, respectively.
Total amortization expense for intellectual property agreements for the three months ended May 31, 2019 and 2018 was $232,292 and $231,042, respectively, and total amortization expense for the nine months ended May 31, 2019 and 2018 was $696,876 and $693,125 respectively.
Amortization of software development costs amounted to $322,552 and $331,862 for the three months ended May 31, 2019 and 2018, respectively, and $1,006,339 and $952,894 for the nine months ended May 31, 2019 and 2018, respectively.
Rent expense, including common area maintenance fees for the three months ended May 31, 2019, and 2018 was $147,581 and $144,589, respectively, and $436,357 and $424,077 for the nine months ended May 31, 2019 and 2018, respectively.
Our contributions to this Plan amounted to $116,839 and $95,585 for the three months ended May 31, 2019 and 2018, respectively and $295,777 and $238,011 for the nine months ended May 31, 2019 and 2018 respectively.
Prior to this lease DILIsym was on a month-to-month rental.Consolidated gross margin increased $2.10 million or 12.3%, to $19.21 million in 9moFY19 from $17.10 million in 9moFY18.
The change is mainly due to the effect of lower Federal rates enacted at the beginning of 2018.
The effective rate for the nine months was an expense of 23.9% compared to a expense of 8.5% in the prior year.
Direct expenses on contracts increased by $104,000 this fiscal quarter compared to the prior year but we offset by $100,000 of lower testing costs in the period.
During the period direct contract costs decreased by approximately $99,000.
Net income increased by $483,000 million, or 20.1%, in 3QFY19 to $2.9 million from $2.4 million in 3QFY18.
Total research and development cost increased $274,000 in 9moFY19 compared to 9moFY18.
Total research and development cost increased $73,000 in 3QFY19 compared to 3QFY18.
In addition, we actively seek strategic acquisitions to expand the pharmaceutical software and services business.